Pasireotide in the treatment of neuroendocrine tumors: a review of the literature

High interlaboratory and interobserver agreement of somatostatin receptor immunohistochemical determination and correlation with response to somatostatin analogs

(2018) Atsuko Kasajima et al.   HUMAN PATHOLOGY

Somatostatin analogs in the treatment of neuroendocrine tumors: current and emerging aspects

(2017) Gherardo Mazziotti et al.   EXPERT OPINION ON PHARMACOTHERAPY

Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial

(2017) Piero Ferolla et al.   LANCET ONCOLOGY

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents

(2017) Marianne Pavel et al.   NEUROENDOCRINOLOGY

Phase I dose-escalation study of long-acting pasireotide in patients with neuroendocrine tumors

(2017) James Yao et al.   OncoTargets and Therapy

Role of tumor microenvironment in tumorigenesis

(2017) Maonan Wang et al.   Journal of Cancer

Pasireotide Therapy of Multiple Endocrine Neoplasia Type 1–Associated Neuroendocrine Tumors in Female Mice Deleted for an Men1 Allele Improves Survival and Reduces Tumor Progression

(2016) Gerard V. Walls et al.   ENDOCRINOLOGY

Effects of Somatostatin Analogs and Dopamine Agonists on Insulin-Like Growth Factor 2-Induced Insulin Receptor Isoform A Activation by Gastroenteropancreatic Neuroendocrine Tumor Cells

(2016) Roxanne C.S. van Adrichem et al.   NEUROENDOCRINOLOGY

Anti-metastatic potential of somatostatin analog SOM230: Indirect pharmacological targeting of pancreatic cancer-associated fibroblasts

(2016) Siham Moatassim-Billah et al.   Oncotarget

Somatostatin Receptor 2 and 5 Expressions in Gastroenteropancreatic Neuroendocrine Tumors in Turkey

(2015) Omer Yerci et al.   Asian Pacific Journal of Cancer Prevention

Phase I study of combination of pasireotide LAR + gemcitabine in locally advanced or metastatic pancreatic cancer

(2015) Yaman Suleiman et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance

(2015) C. Duluc et al.   EMBO Molecular Medicine

Phase I trial of combination of FOLFIRI and pasireotide, a somatostatin analogue, in advanced gastrointestinal malignancies

(2015) Amit Mahipal et al.   INVESTIGATIONAL NEW DRUGS

Expression of Somatostatin Receptors 1-5 and Dopamine Receptor 2 in Lung Carcinoids: Implications for a Therapeutic Role

(2015) George Kanakis et al.   NEUROENDOCRINOLOGY

Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues

(2015) Edward Wolin et al.   Drug Design Development and Therapy

RAF signaling in neuroendocrine neoplasms: From bench to bedside

(2014) Nicola Fazio et al.   CANCER TREATMENT REVIEWS

Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures

(2014) A. Mohamed et al.   ENDOCRINE-RELATED CANCER

Hallmarks of gastrointestinal neuroendocrine tumours: implications for treatment

(2014) Annemiek Walenkamp et al.   ENDOCRINE-RELATED CANCER

Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors

(2014) M Cives et al.   ENDOCRINE-RELATED CANCER

Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors

(2014) Martyn E. Caplin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study

(2013) Edward M. Wolin et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Neuroendocrine tumors: insights into innovative therapeutic options and rational development of targeted therapies

(2013) Federica Barbieri et al.   DRUG DISCOVERY TODAY

Hyperglycemia Associated With Pasireotide: Results From a Mechanistic Study in Healthy Volunteers

(2013) Robert R. Henry et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The Novel Somatostatin Receptor 2/Dopamine Type 2 Receptor Chimeric Compound BIM-23A758 Decreases the Viability of Human GOT1 Midgut Carcinoid Cells

(2013) Kathrin Zitzmann et al.   NEUROENDOCRINOLOGY

Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors

(2012) Jennifer A Chan et al.   ENDOCRINE-RELATED CANCER

Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study

(2012) Larry K Kvols et al.   ENDOCRINE-RELATED CANCER

Signaling Pathways as Specific Pharmacologic Targets for Neuroendocrine Tumor Therapy: RET, PI3K, MEK, Growth Factors, and Notch

(2012) Yvette Carter et al.   NEUROENDOCRINOLOGY

Synergistic Effect of Pasireotide and Teriflunomide in Carcinoids in vitro

(2012) Yash Somnay et al.   NEUROENDOCRINOLOGY

Differential expression of somatostatin receptors 1–5 in neuroendocrine carcinoma of the lung

(2012) Koji Tsuta et al.   PATHOLOGY RESEARCH AND PRACTICE

Pasireotide (SOM230) is effective for the treatment of pancreatic neuroendocrine tumors (PNETs) in a multiple endocrine neoplasia type 1 (MEN1) conditional knockout mouse model

(2012) Thomas J. Quinn et al.   SURGERY

Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT

(2011) Bernhard Svejda et al.   CANCER

SOM230 combined with celecoxib prolongs the survival in nude mice with HepG-2 xenografts

(2011) Yan Xie et al.   CANCER BIOLOGY & THERAPY

Expression of somatostatin receptors, dopamine D2 receptors, noradrenaline transporters, and vesicular monoamine transporters in 52 pheochromocytomas and paragangliomas

(2011) A. Saveanu et al.   ENDOCRINE-RELATED CANCER

The role of somatostatin and dopamine D2 receptors in endocrine tumors

(2011) Federico Gatto et al.   ENDOCRINE-RELATED CANCER

Somatostatin-Dopamine Chimeras: A Novel Approach to Treatment of Neuroendocrine Tumors

(2011) M. Culler   HORMONE AND METABOLIC RESEARCH

Current Scientific Rationale for the Use of Somatostatin Analogs and mTOR Inhibitors in Neuroendocrine Tumor Therapy

(2011) Corinne Bousquet et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Synergistic anti-tumor effects of RAD001 with MEK inhibitors in neuroendocrine tumors: A potential mechanism of therapeutic limitation of mTOR inhibitor

(2011) Shinya Iida et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Clinical Significance of Protein Expression of Cyclooxygenase-2 and Somatostatin Receptors in Gastroenteropancreatic Neuroendocrine Tumors

(2011) Hee Sung Kim et al.   Cancer Research and Treatment

Compensatory activation of Akt in response to mTOR and Raf inhibitors – A rationale for dual-targeted therapy approaches in neuroendocrine tumor disease

(2010) Kathrin Zitzmann et al.   CANCER LETTERS

Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids

(2010) Maria Chiara Zatelli et al.   ENDOCRINE-RELATED CANCER

Identification of a Novel Raf-1 Pathway Activator that Inhibits Gastrointestinal Carcinoid Cell Growth

(2010) M. R. Cook et al.   MOLECULAR CANCER THERAPEUTICS

Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases

(2009) L. Righi et al.   ANNALS OF ONCOLOGY

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group

(2009) Anja Rinke et al.   JOURNAL OF CLINICAL ONCOLOGY

Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial

(2009) James C. Yao et al.   JOURNAL OF CLINICAL ONCOLOGY

ZM447439, a Novel Promising Aurora Kinase Inhibitor, Provokes Antiproliferative and Proapoptotic Effects Alone and in Combination with Bio- and Chemotherapeutic Agents in Gastroenteropancreatic Neuroendocrine Tumor Cell Lines

(2009) I. Georgieva et al.   NEUROENDOCRINOLOGY

Somatostatin inhibits colon cancer cell growth through cyclooxygenase-2 downregulation

(2008) R Colucci et al.   BRITISH JOURNAL OF PHARMACOLOGY

Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines

(2008) Mark Kidd et al.   CANCER

Immunohistochemical localization of somatostatin receptor subtypes in benign and malignant adrenal tumours

(2008) Nicole Unger et al.   CLINICAL ENDOCRINOLOGY

Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors

(2008) A. Moreno et al.   ENDOCRINE-RELATED CANCER

Effects of somatostatin analog SOM230 on cell proliferation, apoptosis, and catecholamine levels in cultured pheochromocytoma cells

(2008) Daniela Pasquali et al.   JOURNAL OF MOLECULAR ENDOCRINOLOGY